NCT06056830ClinicalTrials.gov
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
בקצרה
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
שלב 3דרושים 383 משתתפים34 אתרים3 מדינות
קטגוריות
רשום במרשם אחד
- ClinicalTrials.govNCT06056830פתיחת רשומה זו ב־ClinicalTrials.govסונכרן השבוע שעבר
מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.
מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.
מתעניינים במחקר הזה?
התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2023-09-28; recorded start 2023-12-21
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
- Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Clarity Pharmaceuticals Ltd)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Allocation not stated in the record
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 31 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 383 participants (target), run at 34 sites, across 3 countries.
How this score is built
- Enrolment25/40
383 participants (target)
- Site count18/25
31 sites
- Country count7/15
3 countries
- Planned duration8/10
Planned over about 33 months
- Sponsor scale2/10
Clarity Pharmaceuticals Ltd has led 5 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
תקציר
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
מצבים רפואיים
- Prostate Cancer
- Prostatic Neoplasms
זכאות
| מין | זכר |
|---|---|
| גילאים | 18 Years – ללא מקסימום |
| מתנדבים בריאים | לא |
זכאות כפי שנכתבה במרשם
זכאות במשפטים פשוטים
הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.
תכנון המחקר
| סוג המחקר | התערבותי |
|---|---|
| שלב | שלב 3 |
| הקצאה | לא רלוונטי |
| מודל ההתערבות | SINGLE_GROUP |
| מטרה ראשית | DIAGNOSTIC |
| הסתרה | NONE (0) |
| גיוס | דרושים 383 משתתפים |
נותן חסות ושותפים
- Clarity Pharmaceuticals Ltd נותן חסות
זרועות והתערבויות
- 64Cu-SAR-bisPSMAEXPERIMENTAL
200MBq 64Cu-SAR-bisPSMA.
התערבויות
- תרופה 64Cu-SAR-bisPSMA
All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
מדדי תוצאה
מדד תוצאה ראשוני
Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases
Independent primary endpoints for Day 1 and Day 2 PET: Co-primary endpoint of sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer within the pelvic lymph nodes compared to the Standard of Truth.
מסגרת זמן Up to 16 weeks
מדד תוצאה משני
Safety and tolerability of 64Cu-SAR-bisPSMA
Incidence and severity of treatment-emergent AEs and SAEs following administration of 64Cu-SAR-bisPSMA
מסגרת זמן Up to 16 weeks
מדד תוצאה משני
Consistency of 64Cu-SAR-bisPSMA PET/CT interpretations for the three central readers
Inter-reader reliability of agreement estimated with a multiple-reader kappa statistic
מסגרת זמן Up to 16 weeks
מדד תוצאה משני
PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs
PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth
מסגרת זמן Up to 16 weeks
מדד תוצאה משני
Ability of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer
Sensitivity of 64Cu-SAR-bisPSMA PET to detect PC within the prostate gland compared to the Standard of Truth
מסגרת זמן Up to 16 weeks
מדד תוצאה משני
Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases without subregion matching
Sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth, without the requirement of subregion (Left or Right) matching between 64Cu-SAR-bisPSMA PET and Standard of Truth
מסגרת זמן Up to 16 weeks
תאריכים
| תאריך התחלה | 21 בדצמבר 2023 (בפועל) |
|---|---|
| סיום ראשוני | 1 בספטמבר 2026 (משוער) |
| סיום | 1 בספטמבר 2026 (משוער) |
| פורסם לראשונה | 28 בספטמבר 2023 (בפועל) |
| עודכן לאחרונה | 11 בספטמבר 2026 |
| התוצאות פורסמו | לא צוין ברשומת המרשם |
| המצב אומת לאחרונה | ספטמבר 2026 |
בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.
מיקומים
34 אתרים מגייסים
Australia
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Fiona Stanley Hospital | Murdoch | Western Australia | מגייס |
| RAMSAY HEALTH CARE AUSTRALIA PTY LIMITED (ABN 36 003 184 889) trading as Hollywood Private Hospital | Nedlands | Western Australia | מגייס |
| St. Vincent's Sydney | Sydney | New South Wales | מגייס |
| Princess Alexandra Hospital | Woolloongabba | Queensland | מגייס |
Puerto Rico
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Pan American Center for Oncology Trials, LLC - Ciudadela | San Juan | מגייס |
United States
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Albany Medical College, Department of Urology | Albany | New York | מגייס |
| Urology Austin, PLLC - Research Department | Austin | Texas | מגייס |
| University of Alabama Birmingham Hospital | Birmingham | Alabama | מגייס |
| University of Texas Southwestern Medical Center | Dallas | Texas | מגייס |
| Urology Clinics of North Texas | Dallas | Texas | מגייס |
| Duke University Medical Center | Durham | North Carolina | מגייס |
| NorthShore University Health System, Glenbrook Hospital | Glenview | Illinois | מגייס |
| BAMF Health | Grand Rapids | Michigan | מגייס |
| Corewell Health | Grand Rapids | Michigan | מגייס |
| Indiana University School of Medicine | Indianapolis | Indiana | מגייס |
| Mayo Clinic- Jacksonville | Jacksonville | Florida | מגייס |
| Arkansas Urology Research Center, LLC | Little Rock | Arkansas | מגייס |
| Greater Los Angeles VA Medical Center | Los Angeles | California | מגייס |
| Urology Group of Southern California | Los Angeles | California | מגייס |
| University of Wisconsin | Madison | Wisconsin | מגייס |
| Biogenix Molecular, LLC | Miami | Florida | מגייס |
| Intermountain Health | Murray | Utah | מגייס |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | מגייס |
| Urology Associates of Nashville | Nashville | Tennessee | מגייס |
| Mount Sinai Doctors Urology Faculty Practice | New York | New York | מגייס |
| XCancer Omaha LLC | Omaha | Nebraska | מגייס |
| UC Irvine Health | Orange | California | מגייס |
| Mayo Clinic- Phoenix | Phoenix | Arizona | מגייס |
| Mayo Clinic- Rochester | Rochester | Minnesota | מגייס |
| The Urology Place | San Antonio | Texas | מגייס |
| Oregon Urology | Springfield | Oregon | מגייס |
| Stanford University Medical Center | Stanford | California | מגייס |
| Urologic Specialists | Tulsa | Oklahoma | מגייס |
| Wichita Urology Group | Wichita | Kansas | מגייס |
מסמכי המחקר
לא צורפו מסמכים ברשומת מרשם זו.
שינויים לאורך זמן
- 11 בספטמבר 2026
אתר נוסף
3 sites added (34 total)
3134